Our study included matched samples of whole blood DNA methylation, CSF Aβ <sub>42</sub> , phosphorylated tau <sub>181</sub> (pTau <sub>181</sub> ), and total tau (tTau) biomarkers data, measured on the same subjects and at the same clinical visits from a total of 202 subjects (123 CN or cognitively normal, 79 AD) in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. This evidence concerns the gene MAPT and Alzheimer disease.